Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7352583 | 0.84 | DRD3 (0.51) | SLC6A2SLC6A4DRD2DRD3EPHX1 | |
| SCHEMBL7380008 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7351591 | 0.82 | DRD3 (0.49) | SLC6A2SLC6A4DRD2DRD3EPHX1 | |
| SCHEMBL7347393 | 0.82 | DRD2 (0.44) | SLC6A2SLC6A4DRD2DRD3SMN1; SMN2 | |
| SCHEMBL7382584 | 0.78 | DRD2 (0.55) | SLC6A2SLC6A4DRD2DRD3TACR1 | |
| SCHEMBL7382004 | 0.75 | DRD2 (0.51) | SLC6A2SLC6A4DRD2DRD3EPHX1 | |
| SCHEMBL5511678 | 0.72 | SLC6A2 (0.53) | SLC6A2SLC6A4DRD2DRD3SLC6A3 | |
| SCHEMBL5511676 | 0.72 | SLC6A2 (0.53) | SLC6A2SLC6A4DRD2DRD3SLC6A3 | |
| SCHEMBL4576888 | 0.71 | OPRD1 (0.46) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28943723 | 0.71 | PKM (0.45) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |